Scientists and health experts in Kenya and globally have welcomed the introduction of a generic long-acting HIV injectable, citing its affordability and potential to expand access in low-income countries.
The injectable, Lenacapavir, is expected to play a key role in efforts to eliminate HIV, following UNAIDS’ call for countries to end the epidemic amid funding challenges.
The drug will be made available in at least 120 low-income countries.
The Standard Group Plc is a multi-media organization with investments in media
platforms spanning newspaper print
operations, television, radio broadcasting, digital and online services. The
Standard Group is recognized as a
leading multi-media house in Kenya with a key influence in matters of national
and international interest.